Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$9.64 USD
+0.28 (2.99%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $9.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Mind Medicine (MindMed) Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
MNMD 9.64 +0.28(2.99%)
Will MNMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MNMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNMD
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
MNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
Other News for MNMD
Oppenheimer Reinstates Mind Medicine (MNMD) with Outperform Rating | MNMD Stock News
Mind Medicine (MNMD) Gains Positive Outlook with Oppenheimer's Outperform Rating
Mind Medicine resumed with an Outperform at Oppenheimer
Mind Medicine (MNMD) Upgraded by Oppenheimer with Promising MM120 Outlook
Mind Medicine upgraded at Oppenheimer on lead asset